UK markets closed

Genomic Vision Société Anonyme (0QT4.L)

LSE - LSE Delayed price. Currency in EUR
Add to watchlist
0.0240-0.0075 (-23.88%)
At close: 05:50PM GMT
Full screen
Previous close0.0315
Open0.0000
Bid0.0000 x N/A
Ask0.0000 x N/A
Day's range0.0000 - 0.0000
52-week range
Volume110,432
Avg. volumeN/A
Market capN/A
Beta (5Y monthly)-0.29
PE ratio (TTM)N/A
EPS (TTM)-0.1000
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Business Wire

    Genomic Vision Strengthens Leadership Team With the Appointment of Frederic Hammel as Chief Operating Officer

    BAGNEUX, France, January 24, 2023--Regulatory News: Genomic Vision (Paris:GV) (FR0011799907 – GV, the "Company"), a Euronext-listed biotechnology company that develops products and services for the highly accurate characterization of DNA sequences, today announces the appointment of Frederic Hammel as Chief Operating Officer, further strengthening its leadership team.

  • Globe Newswire

    Genomic Vision announces successful beta testing of FiberSmart®

    GENOMICS | GENETICS | R&D | DIAGNOSIS TESTS Genomic Vision announces successful beta testing of FiberSmart® FiberSmart® is Genomic Vision’s Artificial Intelligence (AI) powered and fully integrated software automating genomic analysisFiberSmart® leverages cutting-edge AI to rapidly analyze DNA replication kinetics and provide a seamless user experienceFiberSmart platform was successfully tested by AstraZeneca and the Fritz Lipmann Institute Bagneux (France), 5 January 2023 - Genomic Vision (FR00

  • Globe Newswire

    Genomic Vision’s cutting-edge TeloSizer® application to be used in cancer research

    GENOMICS | GENETICS | R&D | DIAGNOSIS TESTS Genomic Vision’s cutting-edge TeloSizer® application to be used in cancer research Genomic Vision and CNRS launch a core oncology program with the Cancer Research Center of Marseille to develop companion tests based on TeloSizer® Bagneux (France) – Genomic Vision (FR0011799907 – GV, the “Company”), a Euronext-listed biotechnology company that develops tools and services for the highly accurate characterization of DNA sequences, is pleased to announce a